Sign In
Buy IVBXF
$10.24
-0.190 (-1.83%)
At Close: Jun 03, 2026
China's Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion
12:43am, Wednesday, 22'nd Oct 2025
The tie-up is the latest between Chinese companies and international pharma majors looking to expand their global reach and tap promising drug pipelines developing in China.
China's Innovent signs $11.4 billion cancer therapy deal with Japan's Takeda
08:39pm, Tuesday, 21'st Oct 2025
China's Innovent Biologics said on Wednesday it had signed an $11.4 billion deal with Japan's Takeda Pharmaceutical Co to accelerate the development of its immuno-oncology and antibody-drug conjugate
Innovent's weight-loss drug highlights China challenge for Novo, Lilly
07:03pm, Monday, 22'nd Sep 2025
Innovent Biologics' newly launched weight-loss drug is making inroads in its home market of China, ramping up competition with its Western rivals as it pursues a marketing strategy that is gaining tra
Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes
06:01am, Friday, 19'th Sep 2025
SAN FRANCISCO and SUZHOU, China, Sept. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerci
Innovent's Partner Ollin Announces Clinical Updates on IBI324 (OLN324, VEGF/ANG-2)
12:00am, Thursday, 18'th Sep 2025
SAN FRANCISCO and SUZHOU, China , Sept. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commerc
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the 34th EADV Congress 2025
09:00pm, Monday, 15'th Sep 2025
SAN FRANCISCO and SUZHOU, China , Sept. 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerci
Fangzhou and Innovent Biologics Form Strategic Alliance for AI-Powered Weight Management Solutions
04:29am, Wednesday, 10'th Sep 2025
SHANGHAI, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, signed a strategic partnership with Innovent
SAN FRANCISCO and SUZHOU, China , Sept. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercial
Innovent Announces 2025 Interim Results and Business Updates
06:08am, Wednesday, 27'th Aug 2025
Robust revenue growth and substantial profit improvement Continued exceptional executions under a clear roadmap of dual-driven growth and global innovation SAN FRANCISCO and SUZHOU, China , Aug. 27,
SAN FRANCISCO and SUZHOU, China , Aug. 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company committed to developing, manufacturing and
Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032
08:00pm, Monday, 04'th Aug 2025
SAN FRANCISCO and SUZHOU, China , Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial
SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial
SAN FRANCISCO and SUZHOU, China , June 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercial
SAN FRANCISCO and SUZHOU, China, June 27, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial
Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions
10:02am, Tuesday, 24'th Jun 2025
SAN FRANCISCO and SUZHOU, China , June 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercialize
